Systematic Light Exposure for Fatigue in Breast Cancer Patients

Not Applicable

Completed

• Conditions: Fatigue; Cancer-related Problem/Condition; Circadian Rhythm Disorders
• Interventions: Device: Light Glasses (Comparison); Device: Light Glasses (Experimental)

• Registration Number: NCT03217201
• Lead Sponsor: Icahn School of Medicine at Mount Sinai

Brief Summary

Cancer related fatigue (CRF) is a stressful and constant tiredness related to cancer and/or its treatment. CRF is the most intense during treatment and can severely interfere with activities of daily living, such as tasks that require physical strength or thinking clearly. Prevalence of CRF has been reported to be as high as 94% during chemotherapy and as high as 34% five years after completion of treatment (Rotonda et al. 2013; Minton \& Stone 2008). There is currently no generally-accepted treatment for CRF. However, there is evidence to suggest that light therapy can help with CRF. Non-pharmacological interventions for CRF have also been studied but are costly to implement and involve significant patient burden, particularly among those in active treatment. Given the clinical impact of CRF, the goal of this project is to investigate a novel, low-cost and low-burden intervention for Breast Cancer patients using a particular kind of light treatment called systematic light exposure (sLE) to treat CRF. Two hundred forty-eight breast cancer (BC) patients undergoing adjuvant or neoadjuvant chemotherapy will be recruited from Memorial Sloan Kettering Cancer Center, and City of Hope. The light will be administered by light glasses daily throughout entire duration of chemotherapy. Outcomes will be assessed at eight timepoints during chemo, and a series of follow up assessments at 1 week, 1-month, 3-months and 6-months post-chemotherapy. This study will have major public health relevance as it will determine if an easy-to-deliver, inexpensive, and low patient burden intervention effectively reduces CRF or prevents it from worsening during chemotherapy. Specific Aims: Aim 1: Determine if sLE prevents CRF from worsening in BC patients undergoing chemotherapy Aim 2: Determine whether sLE affects sleep, depression and circadian activity rhythms. Exploratory Aim 3: Investigate sLE normalizes circadian cortisol rhythms. Exploratory Aim 4: Examine whether the effects of sLE on fatigue are moderated/mediated by sleep quality, depression, and/or circadian rhythms.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2017-07-11
• Study First Submitted QC: 2017-07-11
• Study First Posted: 2017-07-14
• Study Start: 2018-01-25
• Primary Completion: 2022-01-26
• Study Completion: 2022-01-26
• Status Verified: 2023-08
• Last Update Submitted: 2023-08-22
• Last Update Posted: 2023-08-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 194

Inclusion Criteria

• Newly diagnosed patients with stage 1 through 3a Breast Cancer scheduled to receive a 12-week, 16-week, 18-week, 20-week, or 24-week chemotherapy regimen, adjuvant, neoadjuvant, or already receiving chemotherapy.
• MSH, COH and MSK can recruit participants schedule to go on aromatase inhibitors after treatment.
• Currently over the age of 18.
• English language proficient.
• Able to provide informed consent.

Read More

Exclusion Criteria

• Under age 18
• Breast cancer patients scheduled to undergo chemo regimen other than the 12-week, 18-week, 20-week, or 24-week regimen
• Stage 3B breast cancer inflammatory or Stage 4 breast cancer
• Pregnancy
• Currently employed in night shift work
• Confounding underlying medical illnesses which may cause fatigue (e.g., severe Anemia not controlled by medication, per self-report corroborated by medical chart review (e.g., Hb<10gm/dl))
• Eye Diseases which limit the ability of light to be processed (e.g., untreated cataracts, severe glaucoma, macular degeneration, blindness, pupil dilation problems or retina damage)
• Secondary cancer diagnosis (prior or current) within the past 5 years
• Severe sleep disorders (e.g., Narcolepsy)
• Self- reported history of bipolar disorder or manic episodes (which is a contra-indication for light treatment)
• Severe psychological impairment (e.g., hospitalization for depressive episode in the past 12 months
• Previous use of light therapy to alleviate fatigue or depressive symptoms
• Lives outside of the United States throughout the duration of study

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Adjuvant, Comparison Light	Light Glasses (Comparison)	30 minutes of comparison systematic light exposure daily for duration of chemotherapy treatment.
Neo-Adjuvant, Experimental Light	Light Glasses (Experimental)	30 minutes of experimental systematic light exposure daily for duration of chemotherapy treatment.
Adjuvant, Experimental Light	Light Glasses (Experimental)	30 minutes of experimental systematic light exposure daily for duration of chemotherapy treatment.
Neo-Adjuvant, Comparison Light	Light Glasses (Comparison)	30 minutes of comparison systematic light exposure daily for duration of chemotherapy treatment.

Primary Outcome Measures

Name	Time	Method
FACIT-Fatigue Scale	up to 6 months	FACIT-Fatigue Scale - The FACIT-Fatigue scale will be used both for selection of patients into the study and as an outcome measure of fatigue. Smith et al. (1999) report that this 13 item scale has excellent test-retest reliability (r = 0.90) and internal consistency reliability (alpha = 0.93-0.95). In addition, criterion related validity studies using objective measures of physical function as the outcome show that patient reported fatigue based on the FACIT- Fatigue can predict these objective measures. This measure is the main tool for measuring fatigue in the Patient-Reported Outcomes Measurement Information System (PROMIS) initiative. Cella (personal communication) has indicated that a FACIT-Fatigue score equal to or less than 33 constitutes clinically significant fatigue.

Secondary Outcome Measures

Name	Time	Method
The Center for Epidemiological Studies Depression Scale (CES-D)	up to 6 months	The Center for Epidemiological Studies Depression Scale (CES-D) - This 20 item self-report adult instrument is designed to measure common symptoms of depression that have occurred over the past week such as poor appetite, hopelessness, pessimism, and fatigue. Internal consistency using coefficient alpha is estimated to be 0.85 for the general, healthy population, and 0.90 among depressed patient samples.
Credibility/Expectancy Questionnaire	up to 6 months	This questionnaire will ask the patient to report whether the patient feels the light box is a useful treatment for CRF. Patient Assessment of Own Functioning Inventory (PAOFI) a 33-item self- report measure of a patient's self-perceptions regarding their functioning in everyday tasks and activities.
Chronotype (MEQ)	up to 6 months	The study team will collect data on baseline circadian predispositions using the Morningness-Eveningness Questionnaire, a 19-item self-rated survey designed to measure whether a person's peak alertness is in the morning or the evening. Takes approximately 2 minutes to complete.
The Pittsburgh Sleep Quality Index	up to 6 months	The Pittsburgh Sleep Quality Index consists of 19 self-rated items. Scale reliability is excellent using both an internal consistency criterion (Cronbach's alpha = 0.83) and test-retest reliability (r = 0.85). The validity of the instrument is based on its ability to discriminate patients (those having either sleep problems and/or depressive symptoms) from controls (healthy participants without sleep complaints).

Trial Locations

Locations (3)

Memorial Sloan-Kettering Cancer Center; 🇺🇸 New York, New York, United States

City of Hope Cancer Center; 🇺🇸 Duarte, California, United States

Icahn School of Medicine at Mount Sinai; 🇺🇸 New York, New York, United States